Alaunos Therapeutics, Inc.
TCRT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $3 | $0 |
| % Growth | 100% | -99.8% | 634.2% | – |
| Cost of Goods Sold | $0 | $5 | $0 | $0 |
| Gross Profit | $0 | -$5 | $3 | $0 |
| % Margin | 100% | -95,960% | 100% | 100% |
| R&D Expenses | $0 | $16 | $25 | $50 |
| G&A Expenses | $4 | $12 | $13 | $28 |
| SG&A Expenses | $4 | $12 | $13 | $28 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | -$0 | $1 |
| Operating Expenses | $5 | $29 | $38 | $78 |
| Operating Income | -$5 | -$34 | -$35 | -$78 |
| % Margin | -48,120% | -685,340% | -1,201.4% | -19,484.7% |
| Other Income/Exp. Net | $0 | -$1 | -$3 | -$1 |
| Pre-Tax Income | -$5 | -$35 | -$38 | -$79 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$35 | -$38 | -$79 |
| % Margin | -46,790% | -702,800% | -1,291.2% | -19,786.7% |
| EPS | -2.92 | -21.97 | -25.97 | -53.8 |
| % Growth | 86.7% | 15.4% | 51.7% | – |
| EPS Diluted | -2.92 | -21.97 | -25.97 | -53.8 |
| Weighted Avg Shares Out | 2 | 2 | 1 | 1 |
| Weighted Avg Shares Out Dil | 2 | 2 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $2 | $3 | $1 |
| Depreciation & Amortization | $0 | $2 | $3 | $3 |
| EBITDA | -$5 | -$31 | -$32 | -$75 |
| % Margin | -46,770% | -618,080% | -1,088.9% | -18,835.4% |